Vivos Therapeutics eyes positive cash flow as it continues cost-reduction success in Q3
Portfolio Pulse from
Vivos Therapeutics reported a strong Q3 with a 17% increase in revenue and reduced operating expenses, aiming for positive cash flow.
November 14, 2024 | 10:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Vivos Therapeutics reported a 17% increase in Q3 revenue to $3.9 million and reduced operating expenses, indicating strong financial performance and a focus on achieving positive cash flow.
The 17% increase in revenue and reduced operating expenses suggest improved financial health and operational efficiency, likely boosting investor confidence and positively impacting the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100